Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its promising portfolio of novel therapies targeting metabolic and endocrine disorders. With a..

Viking Therapeutics, Inc. (NASDAQ: VKTX) stands out in the biotechnology sector with a remarkable potential upside of 240.62% according to analyst ratings. This company, headquartered in San Diego, California, is..

Viking Therapeutics, Inc. (NASDAQ: VKTX) has been capturing investor interest with its promising pipeline of novel therapies and a staggering potential upside of 263.09%, according to analyst ratings. As a..

Viking Therapeutics, Inc. (NASDAQ: VKTX) is capturing investor attention with its strong potential for substantial gains. Known for its innovative approach in the biotechnology sector, Viking Therapeutics is carving its..

Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, has been capturing the attention of investors with its compelling pipeline of novel therapies aimed at treating metabolic and endocrine disorders...

Viking Therapeutics, Inc. (NASDAQ: VKTX), a promising player in the biotechnology sector, is drawing significant attention from investors with its robust pipeline of clinical-stage therapeutics. Headquartered in San Diego, California,..

Viking Therapeutics, Inc. (VKTX) is capturing the attention of investors with its promising pipeline and remarkable potential for growth. The San Diego-based biotechnology company, with a market capitalization of $3.03..